The specimen core supports all activities of the UCSD SPOTRIAS site, and the SPOTRIAS national network, by arranging for the collection, storage, and shipment of specimens from patients with acute stroke, TIA, and mimic conditions.
Specific Aim 1 continues our routine procedures to obtain, process, and store blood specimens from acute patients at multiple time points. We have established blood-drawing protocols in the emergency departments, intensive care units, and general wards at our collaborating sites. A number of procedures ensure quality handling and labeling of all SPOTRIAS specimens.
Specific Aim 2 proposes to derive a panel of serum markers designed to help predict future ischemic events after transient ischemic attack (TIA). It is important to attempt to stratify TIA patients into high- and low-risk groups, and neither the ABCD2 model nor serum biomarkers has been prospectivelv validated for this purpose. We will derive a multi-marker panel that shows good predictive value for estimating subsequent stroke risk, and then compare the predictive value of the derived biomarker panel to the ABCD2 method. After consent, blood samples will be drawn as soon as practical after admission of TIA patients. Blood will be shipped to Biosite, Inc., for assay. The primary endpoint will be the 90-day incidence of new stroke after TIA. Secondary endpoints will be the 90-day NIHSS and modified Rankin Scale. We will also compute an ABCD2 prediction for each patient. We expect the clinical estimate, ABCD2, to predict subsequent stroke risk with reasonable predictive value. We expect to be able to derive a multi-marker panel of biomarkers that also has a reasonable AUC for the ROC curve. We will determine whether either method is superior to the other.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Chen, P M; Nguyen, D T; Ho, J P et al. (2018) Factors Influencing Acute Stroke Thrombolytic Treatments in Hispanics In the San Diego Region. Austin J Cerebrovasc Dis Stroke 5:
Lyden, Patrick; Hemmen, Thomas; Grotta, James et al. (2016) Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). Stroke 47:2888-2895
Guluma, Kama Z; Liebeskind, David S; Raman, Rema et al. (2015) Feasibility and Safety of Using External Counterpulsation to Augment Cerebral Blood Flow in Acute Ischemic Stroke-The Counterpulsation to Upgrade Forward Flow in Stroke (CUFFS) Trial. J Stroke Cerebrovasc Dis 24:2596-604
Neil, William P; Raman, Rema; Hemmen, Thomas M et al. (2015) Association of Hispanic ethnicity with acute ischemic stroke care processes and outcomes. Ethn Dis 25:19-23
Schlick, Konrad H; Hemmen, Thomas M; Lyden, Patrick D (2015) Seizures and Meperidine: Overstated and Underutilized. Ther Hypothermia Temp Manag 5:223-7
Spokoyny, Ilana; Raman, Rema; Ernstrom, Karin et al. (2015) Defining mild stroke: outcomes analysis of treated and untreated mild stroke patients. J Stroke Cerebrovasc Dis 24:1276-81
Spokoyny, Ilana; Raman, Rema; Ernstrom, Karin et al. (2015) Accuracy of First Recorded ""Last Known Normal"" Times of Stroke Code Patients. J Stroke Cerebrovasc Dis 24:2467-73
Coffman, Clarity R; Raman, Rema; Ernstrom, Karin et al. (2015) The ""DeyeCOM Sign"": Predictive Value in Acute Stroke Code Evaluations. J Stroke Cerebrovasc Dis 24:1299-304
Lyden, Patrick D; Hemmen, Thomas M; Grotta, James et al. (2014) Endovascular therapeutic hypothermia for acute ischemic stroke: ICTuS 2/3 protocol. Int J Stroke 9:117-25
Spokoyny, Ilana; Raman, Rema; Ernstrom, Karin et al. (2014) Imaging negative stroke: diagnoses and outcomes in intravenous tissue plasminogen activator-treated patients. J Stroke Cerebrovasc Dis 23:1046-50

Showing the most recent 10 out of 53 publications